Prostate cancer: A comprehensive review

Medical Oncology

Volumn 17, Issue 2, 2000, Pages 85-105

  Pentyala, S N ^a   Lee, J ^a   Hsieh, K ^a   Waltzer, W C ^a   Trocchia, A ^a   Musacchia, L ^a   Rebecchi, M J ^a   Khan, S A ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Diagnosis; Grading; Management; Prostate cancer; Prostatectomy; Screening; Staging

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DRUG INDUCED DISEASE; ERECTILE DYSFUNCTION; GENE THERAPY; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; THROMBOEMBOLISM;

EID: 0034082198     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02796203     Document Type: Review

References (191)

1. 1 Pienta K.J. Etiology, epidemiology, and prevention of carcinoma of the prostate. In: Walsh PC et al. (eds). Campbell's Urology, 7th edn. Saunders: Philadelphia, 1998.
2. 2 Littrup PJ. Future benefits and cost effectiveness of prostate carcinoma screening. Cancer 1997; 80: 1864-1870.
3. 3 Boring CC, Squires TS, Tong T. Cancer statistics, 1992. Cancer 1992; 42: 19-39.
4. 4 Demers RY, Swanson GM, Weiss LK, Kau TY. Increasing incidence of cancer of the prostate. Arch Intern Med 1994; 154: 1211-1216.
5. 5 Catalona WJ et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
6. 6 Shalala DE. Cancer death rate decline for the first time ever in the 1990's [press release]. National Cancer Institute Bethesda, MD 1996.
7. 7 Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62(6): 1425-1438.
8. 8 Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH. Familial prostate cancer: a different disease? J Urol 1997; 158(6): 2197-2201.
9. 9 Smith JR et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371-1374.
10. 10 Carter BS et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802.
11. 11 Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-71.
12. 12 deVere White RW et al. Racial differences in clinically localized prostate cancers in black and white men. J Urol 1998; 159: 1979-1982.
13. 13 Ingles SA et al. Association of prostate cancer with vitamin D receptor haplotypes in African Americans. Cancer Res 1998; 58: 1620-1623.
14. 14 Devgan SA et al. Genetic variation of 3 beta-hydroxy-steroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 1997; 33: 9-12.
15. 15 Giles G, Ireland P. Diet, nutrition and prostate cancer. Int J Cancer 1997; 10(Suppl): 13-17.
16. 16 Willett WC, Hunter DJ. Vitamin a and cancers of the breast, large bowel, and prostate: epidemiologic evidence. Nutr Rev 1994; 52(2 pt 2): S553-S59.
17. 17 Catalona WJ et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283-1290.
18. 18 Mettlin CJ et al. American Cancer Society-National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen. Cancer 1993; 71: 891-898.
19. 19 Noldus J et al. The value of the ratio of free to total prostate specific antigen for staging purposes in previously untreated prostate cancer. J Urol 1998; 159: 2004-2007.
20. 20 Abdalla I, Ray P, Ray V, Vaida F, Vijayakumar S. Comparison of serum prostate specific antigen levels and PSA density in African-American, white, and Hispanic men without prostate cancer. Urology 1998; 51: 300-305.
21. 21 Henderson RJ et al. Prostate specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 1997; 89: 134-138.
22. 22 Smart CR. The result of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80: 1835-1844.
23. 23 McNeal JE. Zonal anatomy of the prostate. Prostate 1981; 2: 35-49.
24. 24 Allsbrook WC Jr, Simms WW. Histochemistry of the prostate. Hum Pathol 1992; 23: 297-305.
25. 25 Leong AS, Gilham P, Milos J. Cytokeratin and vimentin intermediate filaments proteins in benign and neoplastic prostatic epithelium. Histopathology 1988; 13: 435-442.
26. 26 Ruizeveld de Winter JA et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735-746.
27. 27 Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic and neoplastic human prostate: simultaneous demonstration of cell specific epithelial markers. Hum Pathol 1994; 25: 42-46.
28. 28 Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13: 389-396.
29. 29 O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 1990; 417: 191-196.
30. 30 Kramer CE, Epstein JI. Nucleoli in low grade prostate adenocarcinoma and adenosis. Hum Pathol 1993; 24: 618-623.
31. 31 Howat AJ, Mills PM, Lyons TJ, Stephenson TJ. Absence of S-100 protein in prostate glands. Histopathology 1988; 13: 468-470.
32. 32 Bonkhoff H, Remberger K. Widespread distrubution of nuclear androgen receptor in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anal Histopathol 1993; 422: 35-38.
33. 33 Aprikian AG, Cordan-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993; 7: 3952-3965.
34. 34 Davis NS, DiSant'Agnese PA, Ewing JF, Mooney RA. The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland. J Urol 1989; 142: 884-888.
35. 35 Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat Histopthol 1993; 423: 291-294.
36. 36 Pentyala SN, Whyard TC, Waltzer WC, Meek AG, Hod Y. Androgen induction of urokinase gene expression in lncap cells is dependent on their interaction with the extracellular matrix. Cancer Lett 1998; 130: 121-126.
37. 37 Chung LW, Gleave ME, Hsieh JT, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormonal responsiveness. Cancer Surv 1991; 11: 91-121.
38. 38 Cunha GR, Chung LWK, Sannon JM, Taguihi O, Fujii H. Hormone induced morphogenesis and growth: role of mesenchynal interactions. Recent Prog Horm Res 1993; 39: 559-598.
39. 39 Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5a-androstan-17b-ol-3-one by rat prostate. J Biol Chem 1968a; 243: 5953-5960.
40. 40 Bruchovsky N, Wilson JD. The conversion of testosterone to 5a-androstan-17b-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968b; 243: 2012-2021.
41. 41 Harper ME, Pike A, Peeling WB, Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974; 60: 117-125.
42. 42 Harper ME, Pike A, Peeling WB, Griffiths K. Adrenal androgens and the prostate. In: Motta M, Serio M (eds.) Hormonal Therapy of Prostatic Disease: Basic and Clinical Aspects. Medicom Europe: Amsterdam, pp. 81-94, 1988.
43. 43 Labrie F et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579-594.
44. 44 Denis LJ. Contreversies in the management of localized and metastatic prostate cancer. Eur J Cancer 1991; 27: 333-341.
45. 45 Osman I et al. Chromosome 16 in primary prostate cancer: a microsatellite analysis. Int J Cancer 1997; 71: 580-584.
46. 46 Latil A et al. Molecular analysis of the fhit gene in human prostate cancer. Oncogene 1998; 16: 1863-1868.
47. 47 Latil A, Lidereau R. Genetic aspects of prostate cancer. Virchows Arch 1998; 432: 389-406.
48. 48 Achibarou A et al. Urokinase over production results in increased skeletal muscle metastasis by prostate cancer in vitro. Cancer Res 1994; 54: 2373-2377.
49. 49 Ke YQ et al. Elevated expression of calcium-binding protein p9ka isassociated with increasing malignant characteristics of ratprostate carcinoma cells. Int J Cancer 1997; 71: 832-837.
50. 50 Guo YP, Jacobs SC, Kyprianou N. Down-regulation of protein and mrna expression fortransforming growth factor-beta (tgf-beta-1) type i and type iireceptors in human prostate cancer. Int J Cancer 1997; 71: 573-579.
51. 51 Reiter RE et al. Ti. Prostate stem cell antigen - a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-1740.
52. 52 Latil A. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 1997; 57: 1058-1062.
53. 53 Dong JT et al. Down regulation of the KAI1 metastasis suppressor gene during the progresion of human prostatic cancer infrequently involve gene mutation or allelic loss. Cancer Res 1996; 56: 4387-4390.
54. 54 Richmond PJM, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant ecadherin and alpha-catenin expression in prostatecancer - correlation with patient survival. Cancer Res 1997; 57: 3189-3193.
55. 55 Fry DE, Amin M, Harbrecht PJ. Rectal obstruction secondary to carcinoma of the prostate. Ann Surg 1979; 189: 488-492.
56. 56 Celebi MM, Venable DD, Nopajaroonsri C, Eastham JA. Prostate cancer metastatic only to the penis. South Med J 1997; 90: 959-961.
57. 57 Harada M, Iida M, Yamaguchi, Shida K. Analysis of bone metastasis of prostate adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol 1992; 324: 173-182.
58. 58 Harada M, Shimizu A, Nakamura Y, Nemoto R. Role of the vertebral venous system in metastatic spread of cancer cells to the bone. Adv Exp Med Biol 1992; 324: 83-92.
59. 59 Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 1998; 90: 118-123.
60. 60 Robbins SE et al. Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen independent growth in human prostate cancer cells. Prostate 1996; 29: 362-370.
61. 61 Shevrin DH, Kukreja SC, Ghosh L, Lad TE. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Exp Metastasis 1988; 6: 401-409.
62. 62 Walsh PC, Partin AW. Family history facilitates the early diagnosis of prostate carcinoma. Cancer 1997; 80: 1871-1874.
63. 63 Tanase K, Moriyama N, Muranaka K. Retrovesical liposarcoma: a case report, Hinyokika Kiyo 1998; 44: 105-107.
64. 64 Burchard BE. Blumer's shelf tumor with primary carcinoma of the lung. A case report. J Int Coll Surg 1965; 44: 477-481.
65. 65 Arcangeli CG et al. Percentage of free serum prostate specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998; 51: 558-564.
66. 66 Catalona WJ et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multi-center clinical trial. JAMA 1998; 279(19): 1542-1547.
67. 67 Benson MC, Whang IS, Olsson CA, Mcmahon DJ, Cooner WH. The use of prostatic specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-821.
68. 68 Oesterling JE et al. Serum prostate specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-864.
69. 69 Bare R, Hart L, McCullough DL. Correlation of prostate specific antigen and prostate specific antigen density with outcome of prostate biopsy. Urology 1994; 43: 191-196.
70. 70 Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152: 1163-1167.
71. 71 Mettlin CJ et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from American Cancer Society National Prostate Detection Project. Cancer 1994; 74: 1615-1620.
72. 72 Brawer MK, Aramburu EAG, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predicive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993; 150: 369-373.
73. 73 Babaian RJ, Kojima M, Ramirez EI, Johnston D. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol 1996; 156: 432-437.
74. 74 Ukimura O, Durrani O, Babaian RJ. Role of PSA and its indiced in determining the need for repeat biopsies. Urology 1997; 50: 66-72.
75. 75 Babaian RJ et al. Evaluation of ProstAsure index in the detection of prostate cancer: a preliminary report. Urology 1998; 51: 132-136.
76. 76 Aarnink RG, Beerlage HP, De La Rosette JJ, Debruyne FM, Wijkstra H. Transrectal ultrasound of the prostate: innovations and future applications. J Urol 1998; 159: 1568-1579.
77. 77 Rifkin MD. Ultrasound of the prostate - applications and indications. Schweiz Med Wochenschr 1991; 121:282-291.
78. 78 Rifkin MD, Alexander AA, Helinek TG, Merton DA. Color Doppler as an adjunct to prostate ultrasound. Scand J Urol Nephrol Suppl 1991; 137: 85-89.
79. 79 Lee F et al. Prostatic evaluation by transrectal sonography: Criteria for diagnosis of early carcinoma. Radiology 1986; 158: 91-95.
80. 80 Hodge KK, McNeil JE, Terris MK, Stamey TA. Random systemic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71.
81. 81 Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false negative sextant prostate biopsies. J Urol 1998; 159: 1247-1250.
82. 82 Chen ME, Troncoso P, Johnston DA, Tang K, Babaian RJ. Optimization of prostate biopsy strategy using computer based analysis. J Urol 1997; 158: 2168-2175.
83. 83 Ellis WJ, Brawer MK. The significance of isoechoic prostatic carcinoma. J Urol 1994; 152: 2304-2307.
84. 84 Eskew LA, Bare RL, McCullough DL. Systematic 5 zone prostate biopsy is superior ro sextant biopsy for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199.
85. 85 Epstein JI, Walsh PC, Sauvegeot J, Carter HB. Use of repeat sextent and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997; 158: 1886-1890.
86. 86 Lee F et al. Use of transrectal ultrasound and prostatic specific antigen in diagnosis of prostatic intaepithelial neoplasia. Urology 1989; 34(Suppl): 4-8.
87. 87 Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD. Transrectal ultrasonography in the diagnosis and staging of prostatic carcinoma. Radiol 1989; 170: 609.
88. 88 Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
89. 89 Seaman EK, Sawczuk IS, Fatal M, Olsson CA, Shabsigh R. Transperineal prostate needle biopsy guided by transurethral ultrasound in patients without a rectum. Urology 1996; 47: 353-355.
90. 90 Filderman PS, Jacobs SC. Prostatic ultrasound in the patient without a rectum. Urology 1994; 43: 722-724.
91. 91 Ravery V, Boccon-Gibod L. T3 prostate cancer: how reliable is clinical staging. Semin Urol Oncol 1997; 15: 202-206.
92. 92 Kojima M, Troncoso P, Babaian RJ. Influence of non-cancerous prostatic tissue volume on prostate specific antigen. Urology 1998; 51: 293-299.
93. 93 Pannek J et al. The use of percent free prostate specific antigen for staging of clinically localized prostate cancer. J Urol 1998; 159: 1238-1242.
94. 94 Pannek J et al. The role of free/total prostate-specific antigen ration in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology 1996; 48: 51-54.
95. 95 Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The free to total serum prostate-specific antigen ratio for staging prostate carcinoma. J Urol 1997; 157: 544-547.
96. 96 Lerner SE et al. Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 1996; 48: 240-248.
97. 97 Catalona WJ et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-1220.
98. 98 Stamey TA, Chen Z, Prestigiacomo A. Serum prostate specific antigen complexed to alpha I chymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994; 152: 1510-1514.
99. 99 Henricks WH, England BG, Giacherio DA, Oesterling JE, Wojno K.J. Serum percent free PSA does not predict extraprostatic spread of prostate cancer. Am J Clin Pathol 1998; 109: 533-539.
100. 100 Moul JW, Connelly RR, Perahia B, McLeod. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 1998; 159: 935-940.
101. 101 Kurita Y et al. Transition zone volume adjusted prostate specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate specific antigen levels. Eur Urol 1998; 33: 32-38.
102. 102 Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 1998; 159: 1251-1259.
103. 103 Hamper UM, Sheth S, Walsh PC, Holtz PM, Epstein JI. Carcinoma of the prostate: value of transrectal sonography to detect extension into the neurovascular bundle. Am J Rad 1990; 155: 1015-1019.
104. 104 Egan AJ, Bostwick DG. Predication of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997; 21: 1496-1500.
105. 105 Totsuka Y, Ishizaka H, Suzuki K, Yamanaka H. Usefulness of preoperative MRI diagnosis in prostatic adenocarcinoma. Int J Urol 1997; 4: 467-473.
106. 106 Ikonen S et al. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 1998; 159: 915-919.
107. 107 Rorvik J, Halvorsen OJ, Albrektsen G, Haukaas S. Lymphangiography combined with biopsy and computer tomography to detect lymph node metastasis in localized prostate cancer. Scand J Urol Nephrol 1998; 32: 116-119.
108. 108 Lu-Yao GL, Mclerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes. JAMA 1993; 269: 2633-2655.
109. 109 Voges GE, McNeal JE, Redwine EA, Frieha FS, Stamey TA. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 1992; 69: 520-526.
110. 110 Katz AE et al. Enhanced reverse transcriptase polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995; 75: 1642-1648.
111. 111 Ellis WJ, Vassella RL, Corey E. Use of reverse transcriptase polymerase chain reaction (RT-PCR) to detect prostate cancer cells in the blood. J Urol 1996; 155: 378A.
112. 112 Katz AE et al. Molecular staging of genitourinary malignancies. Urology 1996; 47: 948-958.
113. 113 Jaakkola S, Vornanen T, Leinonen J, Rannikko S, Stenman UH. Detection of prostate cell in peripheral blood: Correlation with serum concentrations of prostate specific antigen. Clin Chem 1995; 41: 182.
114. 114 Ghossein RA et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995; 13: 1195.
115. 115 Moreno JG et al. Detection of micrometastasis in patients with prostate cancer. Cancer Res 1992; 52: 6110-6112.
116. 116 Israeli RS et al. Sensitive nested reverse transcriptase polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate specific membrane antigen and prostate specific antigen based assays. Cancer Res 1994; 54: 6306.
117. 117 Seiden MV et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994; 12: 2634-2639.
118. 118 Klein EA. Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view. Semin Radiat Oncol 1998; 8: 87-94.
119. 119 Keyser D et al. Stage T1-2 prostate cancer with pretreatment PSA level 10ng/,mL or less: radiation therapy or surgery? Int J Radiat Oncol Biol Phys 1997; 38: 351-358.
120. 120 Katcher J, Klein E, Kupelian P. Outcome after radiation vs. surgery for stage T1-T2 prostate cancer in patients with minimum 5 year follow up. J Urol 1997; 157: 1631A.
121. 121 Vicini FA, Horowitz EM, Gonzalez J, Martinez AA. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol 1997; 158: 319-325.
122. 122 Mettlin CJ et al. Results of hospital cancer registry surveys by the American College of Surgeons: outcomes of prostate cancer treatments by radical prostatectomy. Cancer 1997, 80: 1875-1881.
123. 123 Littweiler SE, Djavan B, Klopukh B, Richier JC, Roehrborn CG. Radical retropubic prostatectomy in a large metropolitan hospital: changing trends over a 10 year period (1984-1994). Urology 1995; 45: 813-822.
124. 124 Goluboff ER et al. Urinary continence after radical prostatectomy: the Columbia experience. J Urol 1998; 159: 1276-1280.
125. 125 Van Kampen M, De Weerdt W, Van Poppel H, Baert L. Urinary incontinence following transurethral, transvesical and radical prostatectomy. Retrospective study of 489 patients. Acta Urol Belg 1997; 65: 1-7.
126. 126 Kampen MV et al. Prediction of urinary continence following radical prostatectomy. Urol Int 1998; 60: 80-84.
127. 127 Hollabaugh RS Jr, Dmochowski RR, Kneib TG, Steiner MS. Preservation of putative continence nerves during radical prostatectomy leads to more rapid return of urinary continence. Urology 1998; 51: 960-967.
128. 128 Boxer RJ, Kaufman JJ, Goodwin WE. Radical prostatectomy for carcinoma of the prostate: 1951-1976. A review of 329 patients. Urology 1977; 117: 208.
129. 129 Pound CR, Walsh PC, Epstein JI, Chan DW, Partin AW. Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World J Urol 1997; 15: 373-377.
130. 130 Alsikafi NF, Brendler CB. Surgical modifications of radical retropubic prostatectomy to decrease incidence of positive surgical margins. J Urol 1998; 159: 1281-1285.
131. 131 Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR. Laparoscopic radical prostatectomy: initial short term experience. Urology 1997; 50: 854-857.
132. 132 Hachiya T, Endo M, Nogaki J, Ishida H, Okada K. Significance of prostate-specific antigen after radical prostatectomy. Int J Urol 1997; 4: 461-466.
133. 133 Eastham JA, Scardino PT. Radical prostatectomy. In: Walsh PC et al (eds) Campbell's Urology 7th ed. Saunders: Philadelphia, 2560, 1998.
134. 134 Malavaud B et al. Influence of digital rectal massage on urinary prostate-specific antigen: interest for the detection of local recurrence after radical prostatectomy. Prostate 1998; 34: 23-28.
135. 135 Kramer S et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997; 70: 995-999.
136. 136 Bauer JJ et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1998; 159: 929-933.
137. 137 Pettaway CA. Prognostic markers in clinically localized prostate cancer. Tech Urol 1998; 4: 35-42.
138. 138 Lakshmanan Y, Subong ENP, Partin AW. Differential nuclear matrix protein expression in prostate cancers -correlation with pathologic stage. J Urol 1998; 159: 1354-1358.
139. 139 Partin AW et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology 1994; 43: 649-659.
140. 140 Danella J, Steckel J, Dorey F. Detectable prostate specific antigen levels following radical retropubic prostatectomy: relationship of doubling time to clinical recurrence. J Urol 1993; 149: A447.
141. 141 van den Ouden D, Kranse R, Hop WC, van der Kwast TH, Schroder FH. Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. Urol Int 1998; 60: 17-24.
142. 142 D'Amico AV et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-138.
143. 143 Valicenti RK et al. Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer 1998; 82: 1909-1914.
144. 144 Petrovich Z et al. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998; 40: 139-147.
145. 145 Altwein JE. Enhancing the efficacy of radical prostatectomy in locally advanced prostate cancer. Urol Int 1998; 60(Suppl 2): 2-10.
146. 146 Amling CL et al. Preoperative androgen deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol 1997; 154: 222-229.
147. 147 Amling CL et al. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 1997; 154: 215-221.
148. 148 Raymond JF, Vuong M, Russell KJ. Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys 1998; 41: 93-99.
149. 149 Soulen RL et al. Musculoskeletal complications of neutron therapy for prostate cancer. Radiat Oncol Investig 1997; 5: 81-91.
150. 150 Forman JD, Porter AT. The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate. Semin Urol Oncol 1997; 15: 239-243.
151. 151 Tsunemoto H, Yoo SY. Present status of fast neutron therapy in Asian countries. Bull Cancer Radiother 1996; 83(Suppl): 93S-100S.
152. 152 Lindsley KL et al. Clinical trials of neutron radiotherapy in the United States. Bull Cancer Radiother 1996; 83 (Suppl): 78S-86S.
153. 153 Russel KJ, Caplan RJ, Laramore GE, Burnison CM, Maor MH. Photon versus advanced prostate cancer: results of a randomized prospective trial. Int J Radiat Oncol Biol Phys 1994; 28: 47-54.
154. 154 Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998; 159: 173-177.
155. 155 Kahn D et al. Radioimmunoscintigraphy with In-111 labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998; 16: 284-289.
156. 156 Van Erps P, Van Den Weyngaert D, Denis L. Surgery or radiation: is there really a choice for early prostate cancer. Crit Rev Oncol Hematol 1998; 27: 11-27.
157. 157 Porter AT, Littrup P, Grignon D, Forman J, Montie JE. Radiotherapy and cryotherapy for prostate cancer. In: Walsh PL et al (eds.) Campbell's Urology 7th edn. Saunders: Philadelphia, 2606, 1998.
158. 158 Pollack A, Zagars GK. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology 1998; 51: 258-264.
159. 159 Arterbery VE et al. Quality of life after permanent prostate implant. Sem Surg Oncol 1997; 13: 461-464.
160. 160 Nori D, Moni J. Current issues in techniques of prostate brachytherapy. Semin Surg Oncol 1997; 13: 444-453.
161. 161 Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993; 3: 240-249.
162. 162 Hilaris BS. Brachytherapy in cancer of the prostate: an historical prospective. Semin Surg Oncol 1997; 13:399-405.
163. 163 Mohler JL, Williams BT, Freeman JA. Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World J Urol 1997; 15: 364-368.
164. 164 Johansson JE et al. High 10 year survival rate in patients with early, untreated prostate cancer. JAMA 1992; 267: 2191-2196.
165. 165 Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHG-RH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-508.
166. 166 Paulson DF. Multimodal therapy of prostatic cancer. Urology 1981; 17(Suppl): 53-56.
167. 167 Korman LB. Treatment of prostate cancer. Clin Pharm 1989; 8: 412-424.
168. 168 Bruchovsky N, Goldenberg SL, Akakura A, Rennie PS. Luteinizing hormone-releasing hormone agonists in prostate cancer: elimination of flare reaction by pretreatment with cyproterone acetate and low dose diethylstilbestrol. Cancer 1993; 72: 1685-1691.
169. 169 Neuman F, Jacobi GH. Antiandrogens in tumor therapy. Clin Oncol 1982; 1: 41-66.
170. 170 Varenhors E. Orchiectomy. GnRh analogues and antiandrogens in advanced carcinoma of the prostate. Llaekemedelsverket 1993; 3: 89-102.
171. 171 Mahler C, Verhelst J, Denis L. Clinical pharmaco kinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998; 34: 405-417.
172. 172 Montorini R, Pomante R, Diamanti L, Magi-Galluzzi C. Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol Int 1998; 60(Suppl 1): 25-29.
173. 173 Barradell LB, Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostrate cancer. Drugs Aging 1994; 5: 59-80.
174. 174 Drakos PE, Gez E, Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer 1992; 28A: 1932-1933.
175. 175 Watanabe S, Yamasaki S, Tanae A, Hibi I, Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc Committee on Adrocur Users. Lancet 1994; 334: 1567-1568.
176. 176 O'Reilly M et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
177. 177 Pollard M. Effects of linomide on advanced prostate-seminal vesicle cancers in Lobund-Wistar rats. Prostate 1998; 35: 43-49.
178. 178 Joseph IB, Vukanovic J, Isaacs JT. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 1996; 56: 3404-3408.
179. 179 Vukanovic J, Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenenic agent linomide. Cancer Res 1995; 55: 3517-3520.
180. 180 Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997; 32: 284-293.
181. 181 Steiner MS, Anthony CT, Lu Y, Holt JT. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 1998; 9: 747-755.
182. 182 Blackburn RV, Galoforo SS, Cony PM, Lee YJ. Adenoviral mediated transfer of heat inducible double suicide gene into prostate carcinoma cells. Cancer Res 1998; 58: 1358-1362.
183. 183 Eastham JA et al. In vivo gene therapy with p53 and p21 adenovirus for prostate cancer. Cancer Res 1995; 55: 5151-5155.
184. 184 Gotoh A et al. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21[WAF1/ CIP1] and p16 [CDKN4] in human prostate cancers. J Ural 1997; 158: 636-641.
185. 185 Hsiech, JT et al. Tumor suppressive role of androgen regulated epithelial cell adhesion molecule in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 1995; 55: 190-197.
186. 186 Doarai T, Olsson CA, Katz AE, Buttyan R. Development of hemmerhead ribozyme against bcl-2. Preliminary evaluation of potential gene theraprutic agent for hormone-refractory human prostate cancer. Prostate 1997; 32: 246-258.
187. 187 Doarai T, Goluboff ET, Olsson CA, Buttyan R. Development of hemmerhead ribozyme against bcl-2. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 1997a; 17: 3307-3312.
188. 188 Konishi N, Cho M, Yamamoto K, Hiasa Y. Genetic changes in prostate cancer [review]. Pathol Int 1997; 47: 735-747.
189. 189 Homma Y, Kaneko M, Kondo Y, Kawabe K, Kakizoe T. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143. J Natl Cancer Inst 1997; 89(11): 803-807.
190. 190 Hsieh TC, Wu JM. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate 1997; 33: 97-104.
191. 191 Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 1997; 20: 36-39.